Total Debt
The latest quarterly total debt is $948.10M with a quarterly period change of (9.77%). Total debt includes interest-bearing short-term and long-term debt obligations reported on the balance sheet.
PODD Total Debt
Reported quarterly total debt; no daily interpolation.
Quarterly Total Debt History
| Period | Total Debt | % Change |
|---|---|---|
| Q1 2026 | $948.10M | (9.77%) |
| Q4 2025 | $1.05B | +1.89% |
| Q3 2025 | $1.03B | (27.24%) |
| Q2 2025 | $1.42B | (16.40%) |
| Q1 2025 | $1.70B | +19.23% |
| Q4 2024 | $1.42B | +1.69% |
| Q3 2024 | $1.40B | +0.04% |
| Q2 2024 | $1.40B | (0.26%) |
| Q1 2024 | $1.40B | (3.26%) |
| Q4 2023 | $1.45B | +2.00% |
| Q3 2023 | $1.42B | +1.62% |
| Q2 2023 | $1.40B | +0.09% |
| Q1 2023 | $1.40B | (2.53%) |
| Q4 2022 | $1.43B | +1.86% |
| Q3 2022 | $1.41B | (0.34%) |
| Q2 2022 | $1.41B | (0.33%) |
| Q1 2022 | $1.42B | +10.08% |
| Q4 2021 | $1.29B | +0.05% |
| Q3 2021 | $1.29B | +2.37% |
| Q2 2021 | $1.26B | +17.69% |
| Q1 2021 | $1.07B | (0.83%) |
| Q4 2020 | $1.08B | +16.79% |
| Q3 2020 | $921.50M | +1.24% |
| Q2 2020 | $910.20M | +1.25% |
| Q1 2020 | $899.00M | (0.76%) |
| Q4 2019 | $905.90M | (9.38%) |
| Q3 2019 | $999.66M | +61.97% |
| Q2 2019 | $617.18M | +1.21% |
| Q1 2019 | $609.79M | +3.01% |
| Q4 2018 | $591.98M | +1.28% |
| Q3 2018 | $584.49M | +1.28% |
| Q2 2018 | $577.12M | +0.66% |
| Q1 2018 | $573.33M | +1.26% |
| Q4 2017 | $566.17M | +64.13% |
| Q3 2017 | $344.95M | +1.21% |
| Q2 2017 | $340.84M | +1.21% |
| Q1 2017 | $336.76M | +1.12% |
| Q4 2016 | $333.04M | +0.91% |
| Q3 2016 | $330.02M | +85.40% |
| Q2 2016 | $178.00M | (0.07%) |
| Q1 2016 | $178.13M | +0.36% |
| Q4 2015 | $177.49M | (2.49%) |
| Q3 2015 | $182.01M | +0.69% |
| Q2 2015 | $180.77M | (2.03%) |
| Q1 2015 | $184.52M | +8.76% |
| Q4 2014 | $169.66M | (4.47%) |
| Q3 2014 | $177.60M | (11.85%) |
| Q2 2014 | $201.47M | +56.98% |
| Q1 2014 | $128.34M | +5.48% |
| Q4 2013 | $121.68M | +1.57% |
| Q3 2013 | $119.80M | +6.06% |
| Q2 2013 | $112.95M | (6.59%) |
| Q1 2013 | $120.92M | +2.34% |
| Q4 2012 | $118.16M | +2.17% |
| Q3 2012 | $115.65M | +2.14% |
| Q2 2012 | $113.23M | +2.15% |
| Q1 2012 | $110.84M | +2.12% |
| Q4 2011 | $108.54M | +2.09% |
| Q3 2011 | $106.32M | +2.06% |
| Q2 2011 | $104.18M | +47.02% |
| Q1 2011 | $70.86M | +2.05% |
| Q4 2010 | $69.43M | (26.28%) |
| Q3 2010 | $94.18M | +2.04% |
| Q2 2010 | $92.29M | (6.03%) |
| Q1 2010 | $98.22M | +1.28% |
| Q4 2009 | $96.98M | +1.12% |
| Q3 2009 | $95.90M | +15.43% |
| Q2 2009 | $83.08M | +2.01% |
| Q1 2009 | $81.45M | (4.18%) |
| Q4 2008 | $85.00M | +0.00% |
| Q3 2008 | $85.00M | +0.00% |
| Q2 2008 | $85.00M | +254.05% |
| Q1 2008 | $24.01M | (10.00%) |
| Q4 2007 | $26.68M | (9.09%) |
| Q3 2007 | $29.34M | +0.20% |
| Q2 2007 | $29.28M | +0.20% |
| Q1 2007 | $29.23M | +0.01% |
| Q4 2006 | $29.22M | +225.16% |
| Q3 2006 | $8.99M | (8.12%) |
| Q4 2005 | $9.78M | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy